Education
About Us
Working with TipRanks
Follow Us
Integra Lifesciences Holdings Corp. (IART)
NASDAQ:IART
Earnings Data
Report Date
Jul 23, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.44Last Year’s EPS
0.63Same Quarter Last Year
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 05, 2025
|% Change Since: -24.63%
|Next Earnings Date:Jul 23, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture. While there were notable achievements such as revenue growth, strong instrument sales, and progress in the Acclarent integration, there were significant challenges including increased ship holds, negative operating cash flow, and a substantial tariff impact. The adjustment in EPS and organic revenue decline also highlight ongoing issues.Company Guidance
During the Integra LifeSciences First Quarter 2025 Financial Results Call, the company provided guidance for the second quarter and full year 2025. For Q2, Integra expects revenue in the range of $390 million to $400 million, representing a reported decline of 6.8% to 4.4% and an organic decline of 7.5% to 5.1%. Full-year revenue guidance is maintained at $1.65 billion to $1.72 billion, with a reported growth of 2.4% to 6.5% and organic growth of 0.4% to 4.4%. The guidance reflects the impact of newly identified ship holds, anticipated to affect revenue by $55 million to $70 million. Adjusted EPS for Q2 is projected to be between $0.40 and $0.45, with full-year EPS now guided at $2.19 to $2.29, adjusted for recent global tariffs, which are estimated to impact 2025 by approximately $22 million or $0.22 per share.Reported Revenue Growth
Integra LifeSciences reported revenue of $383 million for Q1 2025, representing a growth of 3.7% compared to the previous year.
Strong Performance in Instruments Portfolio
The instruments portfolio delivered 15% growth driven by continued demand in both the hospital and alternate site settings.
Acclarent Integration Progress
The integration of Acclarent contributed approximately $29 million in revenue for the quarter.
Improved Production Yields for Integra Skin
Efforts to enhance production capabilities for Integra Skin are beginning to pay off, with steady yield improvements noted.
Liquidity Position
As of March 31st, Integra had total liquidity of $1.2 billion, including $273 million in cash and short-term investments.
IART Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IART Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2025 | $16.85 | $13.28 | -21.19% |
Feb 25, 2025 | $22.05 | $24.72 | +12.11% |
Nov 04, 2024 | $19.28 | $24.12 | +25.10% |
Jul 29, 2024 | $31.43 | $25.42 | -19.12% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Integra Lifesciences Holdings Corp. (IART) report earnings?
Integra Lifesciences Holdings Corp. (IART) is schdueled to report earning on Jul 23, 2025, TBA Not Confirmed.
What is Integra Lifesciences Holdings Corp. (IART) earnings time?
Integra Lifesciences Holdings Corp. (IART) earnings time is at Jul 23, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IART EPS forecast?
IART EPS forecast for the fiscal quarter 2025 (Q2) is 0.44.